BioEden is the global leader in the extraction and storage of stem cells from dental pulp. The business uses its patented technology to extract mesenchymal stem cells from children’s milk teeth which are then cryogenically frozen and stored for future therapeutic uses.
Park Place advised the BioEden shareholders on the raising of additional funds to assist the business in further exploiting the success of a recently launched sales and subscription model. The funds raised came from a combination of the existing shareholders and a high net worth private investor.
Tony Veverka, CEO of BioEden, said “The involvement of Park Place transformed the whole fund raising process. Their validation and presentation of the investment case together with their extensive network were crucial to the success of this funding round. The new funding structure provides the perfect alignment between the interests of the new investor and those of the existing shareholders. We look forward to enhancing our relationship with Park Place as the BioEden business continues to grow.”
Tim Simpson, who led the fund raising for Park Place, commented “This fund raising provides BioEden with a platform to exploit its market leading position. The use of stem cells for therapeutic treatments is widely recognised as the future of healthcare. BioEden ensures subscribers can take advantage of exciting new therapies as they are developed.”
BioEden is backed by a group of high net worth investors and Finance Yorkshire.